A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2017
The objectives of this study are to evaluate the safety and efficacy of E10030 intravitreous injection when administered in combination with Lucentis® against a control of Lucentis® alone in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).
Epistemonikos ID: 53642f3401dd5b0a9bd9748e40ccc1654ea87af7
First added on: Sep 27, 2020